Literature DB >> 24052157

Lipoprotein metabolism and CKD: overview.

Philip Barter1.   

Abstract

Patients with chronic kidney disease (CKD) frequently display abnormalities of plasma lipids and lipoproteins. These abnormalities include hypertriglyceridemia associated with elevated levels of very low-density lipoproteins (VLDLs) and chylomicrons. There is often also an increase in the concentration of the atherogenic, cholesterol-enriched remnants of VLDLs and chylomicrons. The concentration of low-density lipoprotein cholesterol is usually normal, but there is frequently a decrease in concentration of the cardio-protective high-density lipoproteins. There is also often an increase in the concentration of the atherogenic lipoprotein (a) particles. This article provides an overview of plasma lipoprotein transport and identifies mechanisms responsible for the abnormalities observed in patients with CKD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24052157     DOI: 10.1007/s10157-013-0866-9

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  20 in total

1.  Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.

Authors:  Michelle A Fryirs; Philip J Barter; Mathiyalagan Appavoo; Bernard E Tuch; Fatiha Tabet; Alison K Heather; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-13       Impact factor: 8.311

2.  Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.

Authors:  Nosratola D Vaziri; Jun Yuan; Zhenmin Ni; Susanne B Nicholas; Keith C Norris
Journal:  Clin Exp Nephrol       Date:  2011-10-19       Impact factor: 2.801

Review 3.  Antiinflammatory properties of HDL.

Authors:  Philip J Barter; Stephen Nicholls; Kerry-Anne Rye; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman
Journal:  Circ Res       Date:  2004-10-15       Impact factor: 17.367

4.  Serum Lp(a) levels in patients with moderate renal failure.

Authors:  E Bairaktari; M Elisaf; O Tsolas; K C Siamopoulos
Journal:  Nephron       Date:  1998       Impact factor: 2.847

5.  Selective deficiency of hepatic triglyceride lipase in uremic patients.

Authors:  R Mordasini; F Frey; W Flury; G Klose; H Greten
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

6.  Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.

Authors:  N D Vaziri; K Liang; J S Parks
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

7.  Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.

Authors:  Evagelos N Liberopoulos; Eleni Papavasiliou; George A Miltiadous; Marios Cariolou; Kostas C Siamopoulos; Alexandros D Tselepis; Moses S Elisaf
Journal:  Perit Dial Int       Date:  2004 Nov-Dec       Impact factor: 1.756

8.  Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure.

Authors:  N D Vaziri; K Liang
Journal:  Kidney Int       Date:  1996-12       Impact factor: 10.612

9.  Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia.

Authors:  G F Guarnieri; M Moracchiello; L Campanacci; F Ursini; L Ferri; M Valente; C Gregolin
Journal:  Kidney Int Suppl       Date:  1978-06       Impact factor: 10.545

10.  Increased lipoprotein(a) concentrations in chronic renal failure.

Authors:  S M Haffner; K K Gruber; G Aldrete; P A Morales; M P Stern; K R Tuttle
Journal:  J Am Soc Nephrol       Date:  1992-11       Impact factor: 10.121

View more
  12 in total

1.  Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Authors:  Archna Bajaj; Scott M Damrauer; Amanda H Anderson; Dawei Xie; Matthew J Budoff; Alan S Go; Jiang He; James P Lash; Akinlolu Ojo; Wendy S Post; Mahboob Rahman; Muredach P Reilly; Danish Saleheen; Raymond R Townsend; Jinbo Chen; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-24       Impact factor: 8.311

Review 2.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

3.  Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin.

Authors:  Kwok Leung Ong; David D Waters; Rana Fayyad; Liffert Vogt; Shari Melamed; David A DeMicco; Kerry-Anne Rye; Philip J Barter
Journal:  J Am Heart Assoc       Date:  2018-01-22       Impact factor: 5.501

Review 4.  Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.

Authors:  Eduardo Cambruzzi; Karla Lais Pêgas
Journal:  J Bras Nefrol       Date:  2018-11-08

Review 5.  Lipoproteins as targets and markers of lipoxidation.

Authors:  Catarina B Afonso; Corinne M Spickett
Journal:  Redox Biol       Date:  2018-12-06       Impact factor: 11.799

6.  Predictive value of procalcitonin in chronic allograft dysfunction in kidney transplant recipients.

Authors:  Jing Yao; Lijuan Jiang; Dong Xue; Yanbei Sun
Journal:  Exp Ther Med       Date:  2019-10-21       Impact factor: 2.447

7.  Effect of myeloperoxidase modified LDL on bovine and human aortic endothelial cells.

Authors:  Ghadir El Samad; Samer Bazzi; Marc Karam; Karim Zouaoui Boudjeltia; Luc Vanhamme; Jalil Daher
Journal:  Exp Ther Med       Date:  2019-10-17       Impact factor: 2.447

Review 8.  Role of Myeloperoxidase in Patients with Chronic Kidney Disease.

Authors:  Bojana Kisic; Dijana Miric; Ilija Dragojevic; Julijana Rasic; Ljiljana Popovic
Journal:  Oxid Med Cell Longev       Date:  2016-04-03       Impact factor: 6.543

Review 9.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.

Authors:  Shizuya Yamashita; Daisaku Masuda; Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2020-01-23       Impact factor: 5.113

10.  Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.

Authors:  Hardik Ghelani; Valentina Razmovski-Naumovski; Vamsi Inampudi; Dennis Chang; Srinivas Nammi
Journal:  Biomed Res Int       Date:  2019-11-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.